Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850826 | 0.77 | HDAC6 (0.59) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL1003902 | 0.76 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL12938884 | 0.74 | HDAC6 (0.68) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL1366915 | 0.74 | HDAC6 (0.82) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL12938886 | 0.74 | HDAC6 (0.64) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL28969543 | 0.73 | CYP19A1 (0.65) | HDAC6HDAC1HDAC8HDAC11HDAC3 | |
| SCHEMBL24031073 | 0.73 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL12938894 | 0.73 | HDAC6 (0.63) | HDAC6HDAC1HDAC10HDAC8HDAC11 | |
| SCHEMBL16120091 | 0.73 | PTGER4 (0.42) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL16099308 | 0.71 | HDAC6 (0.60) | HDAC6HDAC1HDAC10HDAC8HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | POLB, APOBEC3C, IDH3A | HDAC6 1168/4885HDAC1 74/4885HDAC10 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.